Latest squamous cell carcinoma Stories
The Friday before Memorial Day is Declared "Don't Fry Day" to Encourage Sun Safety Awareness WASHINGTON, May 26 /PRNewswire-USNewswire/ -- As millions of Americans prepare to enjoy the great outdoors Memorial Day weekend, the National Council on Skin Cancer Prevention reminds everyone to practice sun-safe behaviors - pack those wide-brimmed hats in the suitcase. The incidence of melanoma (the most fatal of skin cancers) continues to rise significantly, at a rate faster than any of the seven...
CALGARY, May 25 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) today announced that it has opened enrollment in its Phase 3 trial examining REOLYSIN in combination with paclitaxel and carboplatin in patients with platinum-refractory head and neck cancers. The Company had previously received approval from the U.S. Food and Drug Administration (FDA) under the Special Protocol Assessment (SPA) process and the U.K. Medicines and Healthcare products...
CALGARY, AB, May 18 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today that a paper entitled "Two-Stage Phase I Dose-Escalation Study of Intratumoural Reovirus Type 3 Dearing and Palliative Radiotherapy in Patients with Advanced Cancers," has been published in the online version of the journal Clinical Cancer Research. The paper covers final results from a Phase Ia/Ib U.K. clinical trial (REO 006) investigating the intratumoural delivery...
WILMINGTON, Mass., May 7 /PRNewswire-FirstCall/ -- DUSA Pharmaceuticals, Inc.(®) (NASDAQ GM: DUSA), a dermatology company that is developing and marketing Levulan(®) Photodynamic Therapy (PDT), today announced that the United States Patent and Trademark Office has issued a notice of allowance for a key patent related to its proprietary PDT light source, the BLU-U(®), Blue Light Photodynamic Therapy Illuminator. The new patent will have method of treatment claims which cover the...
WILMINGTON, Mass., May 6 /PRNewswire-FirstCall/ -- DUSA Pharmaceuticals, Inc. (Nasdaq: DUSA) announces that its corporate highlights and first quarter financial results press release will be issued on Tuesday, May 11(th) at 6:30 a.m. to be followed by a conference call at 8:30 a.m. Tuesday, May 11(th) - 8:30 a.m. E.T. If calling from North America use the following toll-free number: 800-647-4314 International callers use: 502-719-4466 Password - DUSA A replay of the call will be available...
WILMINGTON, Mass., May 4 /PRNewswire/ -- DUSA Pharmaceuticals, Inc.® (Nasdaq GM: DUSA) is proud to be a supporting sponsor of The Skin Cancer Foundation's annual Road to Healthy Skin Tour for the second consecutive year. The Tour offers free full-body skin exams by physicians and provides informational materials to raise awareness about the importance of early detection, prevention and treatment of skin cancer and precancerous growths such as actinic keratoses (AKs). According to The...
Findings pave way for personalizing treatment agents in recurrent, metastatic diseaseMost treatment for advanced head and neck cancer requires chemotherapy with a drug called cisplatin, an inorganic platinum agent that inhibits cell growth. A substantial number of patients do not respond well to this therapy, but oncologists are unable to prescribe alternative agents because they don't know which patients will respond to platinum therapy and which won't. However, new research from Fox Chase...
Esophagectomy is a standard treatment for resectable esophageal carcinoma but relatively few patients are cured. Combined neoadjuvant chemoradiotherapy (CRT) or adjuvant CRT with surgery may improve survival but there is concern about treatment morbidity and the best sequencing of CRT and surgery.A research team from China used a prospective study, based on randomized controlled trial design, to compare preoperative and postoperative CRT to surgery alone in patients with resectable esophageal...
CALGARY, March 30 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today that the Cancer Therapy & Research Center at the University of Texas Health Science Center (CTRC) has started patient enrolment in a U.S. Phase 2 clinical trial using intravenous administration of REOLYSIN(R) in combination with carboplatin and paclitaxel in patients with squamous cell carcinoma of the lungs (SCC lung cancer). The Principal Investigator is Dr. Alain...
BRISTOL, Tenn., March 26 /PRNewswire/ -- Graceway® Pharmaceuticals announced today that the Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for Zyclara(TM), determining it to be safe and effective for the treatment of clinically typical, visible or palpable actinic keratoses (AK). The new treatment can be used on large areas of skin, including the full face or balding scalp on a convenient, 6-week dosing cycle. Zyclara shares the same active ingredient as...
